These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 11291832)

  • 1. The oral fluorinated pyrimidines.
    de Bono JS; Twelves CJ
    Invest New Drugs; 2001; 19(1):41-59. PubMed ID: 11291832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The oral fluoropyrimidines in cancer chemotherapy.
    Lamont EB; Schilsky RL
    Clin Cancer Res; 1999 Sep; 5(9):2289-96. PubMed ID: 10499595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral therapy for colorectal cancer: how to choose.
    Damjanov N; Meropol NJ
    Oncology (Williston Park); 2000 Jun; 14(6):799-807; discussion 807-8, 813-4,. PubMed ID: 10887632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation.
    Milano G; Ferrero JM; François E
    Br J Cancer; 2004 Aug; 91(4):613-7. PubMed ID: 15280932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral DPD-inhibitory fluoropyrimidine drugs.
    Diasio RB
    Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):19-23. PubMed ID: 11098485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral fluoropyrimidines in the treatment of colorectal cancer.
    Meropol NJ
    Eur J Cancer; 1998 Sep; 34(10):1509-13. PubMed ID: 9893621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
    Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
    Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral fluoropoyrimidines.
    Hoff PM; Royce M; Medgyesy D; Brito R; Pazdur R
    Semin Oncol; 1999 Dec; 26(6):640-6. PubMed ID: 10606257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical implications of dihydropyrimidine dehydrogenase inhibition.
    Diasio RB
    Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):17-21. PubMed ID: 10442353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors.
    Schöffski P
    Anticancer Drugs; 2004 Feb; 15(2):85-106. PubMed ID: 15075664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug delivery of oral anti-cancer fluoropyrimidine agents.
    Miura K; Shima H; Takebe N; Rhie J; Satoh K; Kakugawa Y; Satoh M; Kinouchi M; Yamamoto K; Hasegawa Y; Kawai M; Kanazawa K; Fujiya T; Unno M; Katakura R
    Expert Opin Drug Deliv; 2017 Dec; 14(12):1355-1366. PubMed ID: 28379040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovorin (ORZEL) and S-1: a review of their clinical development and therapeutic potential.
    Hoff PM
    Invest New Drugs; 2000 Nov; 18(4):331-42. PubMed ID: 11081569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral fluoropyrimidines: a closer look at their toxicities.
    Macdonald JS
    Am J Clin Oncol; 1999 Oct; 22(5):475-80. PubMed ID: 10521062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The oral fluorouracil prodrugs.
    Pazdur R; Hoff PM; Medgyesy D; Royce M; Brito R
    Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):48-51. PubMed ID: 9830626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of the tumor-activated prodrug of dihydropyrimidine dehydrogenase (DPD) inhibitor, RO0094889 for combination therapy with capecitabine.
    Hattori K; Kohchi Y; Oikawa N; Suda H; Ura M; Ishikawa T; Miwa M; Endoh M; Eda H; Tanimura H; Kawashima A; Horii I; Ishitsuka H; Shimma N
    Bioorg Med Chem Lett; 2003 Mar; 13(5):867-72. PubMed ID: 12617910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Answering patients' needs: oral alternatives to intravenous therapy.
    Borner M; Scheithauer W; Twelves C; Maroun J; Wilke H
    Oncologist; 2001; 6 Suppl 4():12-6. PubMed ID: 11585969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil.
    Yamada Y; Hamaguchi T; Goto M; Muro K; Matsumura Y; Shimada Y; Shirao K; Nagayama S
    Br J Cancer; 2003 Sep; 89(5):816-20. PubMed ID: 12942110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluorouracil (5FU) pharmacokinetics in 5FU prodrug formulations with a dihydropyrimidine dehydrogenase inhibitor.
    Peters GJ; van Groeningen CJ; Giaccone G
    J Clin Oncol; 2001 Nov; 19(22):4267-9. PubMed ID: 11709571
    [No Abstract]   [Full Text] [Related]  

  • 19. Fluorouracil and the new oral fluorinated pyrimidines.
    Kuhn JG
    Ann Pharmacother; 2001 Feb; 35(2):217-27. PubMed ID: 11215843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluoropyrimidines: a critical evaluation.
    Brito RA; Medgyesy D; Zukowski TH; Royce ME; Ravandi-Kashani F; Hoff PM; Pazdur R
    Oncology; 1999 Jul; 57 Suppl 1():2-8. PubMed ID: 10436410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.